

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.



BROAD INTELLIGENCE INTERNATIONAL PHARMACEUTICAL HOLDINGS LIMITED

博智國際藥業控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1149)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09(1) of the Listing Rules. The Board wishes to inform the Shareholders and potential investors of the Company that the financial results of the Group for the year ended 31 December 2008 are expected to decrease significantly as compared to those for the year ended 31 December 2007.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Broad Intelligence International Pharmaceutical Holdings Limited (the “Company” and together with its subsidiaries, the “Group”) pursuant to Rule 13.09(1) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “Listing Rules”).

The board of directors of the Company (the “Board”) wishes to inform the shareholders of the Company (the “Shareholders”) and potential investors that the financial results of the Group for the year ended 31 December 2008 are expected to decrease significantly as compared to those for the year ended 31 December 2007.

The Company considers that the significant decrease in the financial results of the Group for the year ended 31 December 2008 was mainly attributable to the increase in cost of sales and selling expenses and the impairment of Group’s assets.

The Company is in the process of finalising the results of the Group for the financial year ended 31 December 2008. The information contained in this announcement is only a preliminary assessment by the Company based on information currently available and is not based on any figures or information audited by the Company's auditors. The audited results of the Group for the year ended 31 December 2008 are expected to be published before the end of April 2009.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Broad Intelligence International Pharmaceutical Holdings Limited
Zhong Houtai
Chairman

Hong Kong, 1 April 2009

Websites: www.broadintelligence.com.hk
www.irasia.com/listco/hk/broadintelligence

As at the date of this announcement, the executive directors of the Company are Mr. Zhong Houtai, Mr. Zhong Houyao, Mr. Chong Hoi Fung, Mr. Sun Daquan, and Mr. Cheung Chuen, Mr. Pei Renjiu and Mr. Li Kai Ming are the independent non-executive directors of the Company.